
Central Retinal Vein Occlusion - Pipeline Insight, 2025
Description
DelveInsight’s, “Central Retinal Vein Occlusion - Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Central Retinal Vein Occlusion: Overview
Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Non-ischemic CRVO is the most common, accounting for about 70% of cases. Best-corrected visual acuity (BCVA) is often better than 20/200. This activity outlines the evaluation and management of central retinal vein occlusion (CRVO) and reviews the role of the interprofessional team in improving care for patients with this condition. A primary risk factor for the development of central retinal vein occlusion is age, with 90% of patients older than 50 years old. Systemic arterial hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia have all been implicated as other primary risk factors for central retinal vein occlusion. No totally effective medical treatment is available for either the prevention or treatment of central retinal vein occlusion. In patients with central retinal vein occlusion, vascular endothelial growth factor (VEGF) is elevated; this leads to swelling as well as new vessels (neovascularization) that are prone to bleeding. Often treatment involves intravitreal injections of an anti-VEGF drug to reduce the new blood vessel growth and swelling.
""Central Retinal Vein Occlusion - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Central Retinal Vein Occlusion pipeline landscape is provided which includes the disease overview and Central Retinal Vein Occlusion treatment guidelines. The assessment part of the report embraces, in depth Central Retinal Vein Occlusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Central Retinal Vein Occlusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Central Retinal Vein Occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Central Retinal Vein Occlusion Emerging Drugs
Further product details are provided in the report……..
Central Retinal Vein Occlusion: Therapeutic Assessment
This segment of the report provides insights about the different Central Retinal Vein Occlusion drugs segregated based on following parameters that define the scope of the report, such as:
Central Retinal Vein Occlusion: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Retinal Vein Occlusion therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Retinal Vein Occlusion drugs.
Central Retinal Vein Occlusion Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Central Retinal Vein Occlusion: Overview
Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Non-ischemic CRVO is the most common, accounting for about 70% of cases. Best-corrected visual acuity (BCVA) is often better than 20/200. This activity outlines the evaluation and management of central retinal vein occlusion (CRVO) and reviews the role of the interprofessional team in improving care for patients with this condition. A primary risk factor for the development of central retinal vein occlusion is age, with 90% of patients older than 50 years old. Systemic arterial hypertension, open-angle glaucoma, diabetes mellitus, and hyperlipidemia have all been implicated as other primary risk factors for central retinal vein occlusion. No totally effective medical treatment is available for either the prevention or treatment of central retinal vein occlusion. In patients with central retinal vein occlusion, vascular endothelial growth factor (VEGF) is elevated; this leads to swelling as well as new vessels (neovascularization) that are prone to bleeding. Often treatment involves intravitreal injections of an anti-VEGF drug to reduce the new blood vessel growth and swelling.
""Central Retinal Vein Occlusion - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Central Retinal Vein Occlusion pipeline landscape is provided which includes the disease overview and Central Retinal Vein Occlusion treatment guidelines. The assessment part of the report embraces, in depth Central Retinal Vein Occlusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Central Retinal Vein Occlusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Central Retinal Vein Occlusion.
- In the coming years, the Central Retinal Vein Occlusion market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Central Retinal Vein Occlusion R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Central Retinal Vein Occlusion treatment market. Several potential therapies for Central Retinal Vein Occlusion are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Central Retinal Vein Occlusion market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Central Retinal Vein Occlusion) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Central Retinal Vein Occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Central Retinal Vein Occlusion Emerging Drugs
- 610: 3SBio
- GS-101 (Aganirsen): Gene Signal
Further product details are provided in the report……..
Central Retinal Vein Occlusion: Therapeutic Assessment
This segment of the report provides insights about the different Central Retinal Vein Occlusion drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Central Retinal Vein Occlusion
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Central Retinal Vein Occlusion: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Retinal Vein Occlusion therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Retinal Vein Occlusion drugs.
Central Retinal Vein Occlusion Report Insights
- Central Retinal Vein Occlusion Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Central Retinal Vein Occlusion drugs?
- How many Central Retinal Vein Occlusion drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Central Retinal Vein Occlusion?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Central Retinal Vein Occlusion therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Central Retinal Vein Occlusion and their status?
- What are the key designations that have been granted to the emerging drugs?
- 3SBio
- Gene Signal
- Celon pharma
- The Emmes Company, LLC
- 610
- GS-101 (Aganirsen)
- Ranibizumab biosimilar
- Autologous Bone Marrow CD34+ Stem Cells
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Central Retinal Vein Occlusion: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Central Retinal Vein Occlusion – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- 610: 3SBio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Autologous Bone Marrow CD34+ Stem Cells: The Emmes Company, LLC
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Central Retinal Vein Occlusion Key Companies
- Central Retinal Vein Occlusion Key Products
- Central Retinal Vein Occlusion- Unmet Needs
- Central Retinal Vein Occlusion- Market Drivers and Barriers
- Central Retinal Vein Occlusion- Future Perspectives and Conclusion
- Central Retinal Vein Occlusion Analyst Views
- Central Retinal Vein Occlusion Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.